Isocitrate dehydrogenase (IDH) mutation is known to affect the prognosis of patients with glioma [4–6], and the knowledge of IDH mutation has been incorporated into 2021 WHO classification of brain tumors [7]. This evidence concerns the gene IDH3A and central nervous system cancer.